{ "items": [ "\n\n
\n \n 3 June 2015\n \n
\n\n \n \n \n\n \n \n \nThis one day Workshop is being co-hosted by Professor Gary Entrican on 27th October at the Moredun Institute, Edinburgh. It will include a range of presentations focusing on career development in veterinary vaccinology, providing complementary perspectives from funders and successful grant winners. The workshop is designed to educate and provide skills for early career researchers to develop their careers within vaccinology.
\n \n\n\n \n 3 June 2015\n \n
\n\n \n \n \n\n \n \n \nAntigen Discovery and Proteomics of Host Response workshop, hosted at the University of Liverpool on 18th November 2015. \r\n\r\nThe workshop will be hosted at the Foresight Centre and will include a range of presentations focusing on antigen discovery and the proteomics of host response, providing complementary perspectives of both research of the antigen and host response.This workshop is designed to educate researchers in the latest updates on antigen discovery and proteomics of host response as well as the tools and technologies to be able to conduct such research.
\n \n\n\n \n 2 June 2015\n \n
\n\n \n \n \n\n \n \n \nSouth Africa stands at the centre of a global TB epidemic devastating the health of millions and their communities. Oxford University is working with South African researchers, health workers and community volunteers in the hunt for an urgently-needed new vaccine. Professor Helen McShane, Jenner Investigator, has been working with local and international organisations to build a system of trialling vaccines, with the active participation of the local community.
\n \n\n\n \n 8 May 2015\n \n
\n\n \n \n \n\n \n \n \nA vaccine against Malaria, developed at the Jenner Institute, has shown promising results in its first field trial. The trial in Kenya found that the vaccine was 67% effective against Plasmodium falciparum infections - see BBC report.
\n \n\n\n \n 28 April 2015\n \n
\n\n \n \n \n\n \n \n \n24 - 30th April each year is the World Health Organisation World Immunization Week. To mark this occasion, NDM spoke to Professor Simon Draper, a MRC Career Development Fellow based at the Jenner Institute, about making vaccines more effective.\r\n\r\nSimon Draper: A vaccine relies on the remarkable ability of the immune system to recognise what it has seen before - we call this process immunological memory.
\n \n\n\n \n 28 April 2015\n \n
\n\n \n \n \n\n \n \n \nThe last week of April each year is the World Health Organisation Immunization Week. Clinical trials are an essential part of vaccine development and The Jenner Institute has been involved in a fast-tracked Ebola Phase I clinical trial in response to the Ebola outbreak in West Africa.\r\n\r\nNDM spoke to Dr Katie Ewer, a Senior Immunologist involved in this trial, about the need for an Ebola vaccine and what the next steps are.
\n \n\n\n \n 24 April 2015\n \n
\n\n \n \n \n\n \n \n \nThis year\u2019s World Health Organisation (WHO) World Malaria Day (on 25th April) has the theme of \u2018Defeat Malaria\u2019. Nearly half the world\u2019s population is at risk of contracting the disease, and millions are affected by malaria every year. Dr Sumi Biswas work on developing vaccines that block the blood transmission of malaria has won her a Grand Challenges Explorations Award.
\n \n\n\n \n 24 March 2015\n \n
\n\n \n \n \n\n \n \n \nLast year to mark World Tuberculosis Day NDM spoke to Professor Helen McShane to find out more about her research developing an improved TB vaccine. NDM spoke to her again to find out if there have been any developments in the last year.
\n \n\n\n \n 4 March 2015\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford and its Clinical BioManufacturing Facility have approached MHRA in order to receive feedback, guidance and support in the development and manufacture of a candidate vaccine for treatment of malaria that has seen them explore an innovative approach to viral vectors using a chimpanzee virus.
\n \n\n\n \n 2 March 2015\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford is delighted to announce that the first collaborative research projects to be agreed by the University under the Pfizer Rare Disease Consortium have been signed.
\n \n\n\n \n 5 February 2015\n \n
\n\n \n \n \n\n \n \n \nReuters: As West Africa's devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast.
\n \n\n\n \n 5 February 2015\n \n
\n\n \n \n \n\n \n \n \nThe Guardian: The trial conducted at Oxford University paves the way for the vaccine, jointly developed by GlaxoSmithKline (GSK) and the US National Institutes of Health (NIH), to be further tested on patients in west Africa.
\n \n\n\n \n 5 February 2015\n \n
\n\n \n \n \n\n \n \n \nBBC: Sixty healthy volunteers were immunised at the University of Oxford's Jenner Institute. The findings, published in the New England Journal of Medicine, show the vaccine generated an immune response against Ebola. But it is not clear whether the vaccine will offer protection against the disease.
\n \n\n\n \n 5 February 2015\n \n
\n\n \n \n \n\n \n \n \nReuters: First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.
\n \n\n\n \n 5 February 2015\n \n
\n\n \n \n \n\n \n \n \nNature: Safety trials of Ebola vaccines are starting to return results: at least one is known to be safe and to summon an immune response against the virus. The challenge now is to use the results to guide the larger studies that will reveal whether the vaccines work.
\n \n\n\n \n 29 January 2015\n \n
\n\n \n \n \n\n \n \n \nPress release: The first results from the Ebola vaccine trial carried out by the Jenner Institute found that the vaccine has an acceptable safety profile at the doses tested, and is able to generate an immune response. The paper published in the New England Journal of Medicine reports safety data and immune responses for the volunteers for 28 days after immunisation.
\n \n\n\n \n 28 January 2015\n \n
\n\n \n \n \n\n \n \n \nFriday 6th March 2015, Oxford University Museum of Natural History\r\nThe Jenner Institute will be hosting the Opening Event for the Oxfordshire Science Festival, to be held at the University's renowned and beautiful Museum of Natural History.
\n \n\n\n \n 13 January 2015\n \n
\n\n \n \n \n\n \n \n \nA trial of a GSK/NIH candidate Ebola vaccine at Oxford University suggests the vaccine has an acceptable safety profile and is able to generate an immune response.
\n \n\n\n \n 22 December 2014\n \n
\n\n \n \n \n\n \n \n \nThe conference will focus on four themes: Epidemiology and Economics, Novel Tools and Technologies, Protective Immunity and Immunogen Design. Jenner Investigators will participate as speakers and are represented on the Network's coordinating group.
\n \n\n\n \n 18 December 2014\n \n
\n\n \n \n \n\n \n \n \nPress release: Oxford University has been ranked number one in the UK for the quality of its research. The official UK-wide assessment of all university research, the Research Excellence Framework, found that Oxford has the largest volume of world-leading research in the country.
\n \n\n